Capmatinib
What is Capmatinib?[edit | edit source]
- Capmatinib (Tabrecta) is a kinase inhibitor used to treat adults with a kind of lung cancer called non-small cell lung cancer (NSCLC).
What are the uses of this medicine?[edit | edit source]
This medicine is indicated to treat adults with a kind of lung cancer called non-small cell lung cancer (NSCLC) that:
- has spread to other parts of the body or cannot be removed by surgery (metastatic), and
- whose tumors have an abnormal mesenchymal epithelial transition (MET) gene
How does this medicine work?[edit | edit source]
- An orally bioavailable inhibitor of the proto-oncogene c-Met (also known as hepatocyte growth factor receptor (HGFR)) with potential antineoplastic activity.
- Capmatinib selectively binds to c-Met, thereby inhibiting c-Met phosphorylation and disrupting c-Met signal transduction pathways.
- This may induce cell death in tumor cells overexpressing c-Met protein or expressing constitutively activated c-Met protein.
- c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays key roles in tumor cell proliferation, survival, invasion, metastasis, and tumor angiogenesis.
Who Should Not Use this medicine ?[edit | edit source]
- This medication have no usage limitations.
What drug interactions can this medicine cause?[edit | edit source]
- Avoid Coadministration of Tabrecta with a strong CYP3A inhibitor.
- Avoid Coadministration of Tabrecta with a strong CYP3A inducer.
Is this medicine FDA approved?[edit | edit source]
- It was approved for use in the United States in 2020.
How should this medicine be used?[edit | edit source]
Select patients for treatment with Tabrecta based on presence of a mutation that leads to MET exon 14 skipping.
Recommended Dosage
- 400 mg orally twice daily with or without food.
Administration
- Take Tabrecta exactly as your healthcare provider tells you.
- Take Tabrecta 2 times a day with or without food.
- Swallow Tabrecta tablets whole. Do not break, chew, or crush Tabrecta tablets.
- Your healthcare provider may change your dose, temporarily stop, or permanently stop treatment with Tabrecta if you have certain side effects.
- Do not change your dose or stop taking Tabrecta unless your healthcare provider tells you to.
- If you miss or vomit a dose of Tabrecta, do not make up the dose. Take your next dose at your regular scheduled time.
What are the dosage forms and brand names of this medicine?[edit | edit source]
This medicine is available in fallowing doasage form:
- As Tablets: 150 mg and 200 mg
This medicine is available in fallowing brand namesː
- Tabrecta
What side effects can this medication cause?[edit | edit source]
Common possible side effects and laboratory abnormalities of this medicine include:
- swelling of your hands or feet
- nausea
- tiredness and weakness
- vomiting
- loss of appetite
- changes in certain blood test
Tabrecta may cause serious side effects, including:
- lung or breathing problems
- liver problems
- risk of sensitivity to sunlight (photosensitivity)
What special precautions should I follow?[edit | edit source]
- Monitor for new or worsening pulmonary symptoms indicative of ILD/pneumonitis. Permanently discontinue Tabrecta in patients with ILD/pneumonitis.
- May cause hepatotoxicity Monitor liver function tests. Withhold, dose reduce, or permanently discontinue Tabrecta based on severity.
- This medicine may cause photosensitivity reactions. Advise patients to limit direct ultraviolet exposure.
- Advise patients of the potential risk to a fetus and to use effective contraception.
What to do in case of emergency/overdose?[edit | edit source]
- In case of overdose, call the poison control helpline of your country. In the United States, call 1-800-222-1222.
- Overdose related information is also available online at poisonhelp.org/help.
- In the event that the victim has collapsed, had a seizure, has trouble breathing, or can't be awakened, immediately call emergency services. In the United States, call 911.
Can this medicine be used in pregnancy?[edit | edit source]
- Tabrecta can cause fetal harm when administered to a pregnant woman.
- There are no available data on Tabrecta use in pregnant women.
Can this medicine be used in children?[edit | edit source]
- Safety and effectiveness of Tabrecta in pediatric patients have not been established.
What should I know about storage and disposal of this medication?[edit | edit source]
- Dispense in the original package with the desiccant cartridge. Store at 20˚C to 25˚C (68˚F to 77˚F), excursions permitted between 15˚C and 30˚C (59˚F and 86˚F).
- Protect from moisture.
- Discard any unused Tabrecta remaining after 6 weeks of first opening the bottle.
Capmatinib Resources | ||
---|---|---|
|
|
Translate to: East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski
- Need help finding a doctor or specialist anywhere in the world? WikiMD's DocFinder can help with millions of doctors!
This article is a stub. Help WikiMD grow by registering to expand it. |
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.Contributors: Admin, Deepika vegiraju